Xtant Medical Inc. (XTNT)
AMEX: XTNT
· Real-Time Price · USD
0.47
-0.04 (-7.50%)
At close: May 01, 2025, 3:59 PM
0.47
0.15%
After-hours: May 01, 2025, 04:01 PM EDT
Xtant Medical Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Sep 30, 2023 |
|---|---|---|---|
| Orthobiologics Revenue | 16.58M | 15.42M | 15.66M |
| Orthobiologics Revenue Growth | +7.54% | -1.59% | n/a |
| Spinal Implant Revenue | 11.36M | 12.46M | 9.35M |
| Spinal Implant Revenue Growth | -8.82% | +33.17% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2012 |
|---|---|---|---|
| Rest Of World Revenue | 1.19M | 2.31M | 31.95M |
| Rest Of World Revenue Growth | -48.37% | -92.79% | n/a |
| United States Revenue | 52.15M | 62.38M | n/a |
| United States Revenue Growth | -16.40% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 19.38M | 20.89M | 20.25M | 20.45M | 18.23M | 13.67M | 11.94M | 9.8M | 9.57M | 9.43M | 9.18M | 9.46M | 8.37M | 9.76M | 7.88M | 8.62M | 8.31M | 6.83M | 10.73M | 11.77M | 10.84M | 10.11M | 11.06M | 10.76M | 10.53M | 11.99M | 11.74M | 12.6M | 12.21M | 15.76M | 15.27M | 16.42M | 15.17M | 14.37M | 14.05M | 14.86M | 12.46M | 7.51M | 7.21M |
| Selling, General, and Administrative Revenue Growth | -7.22% | +3.20% | -1.01% | +12.19% | +33.35% | +14.51% | +21.84% | +2.41% | +1.42% | +2.78% | -2.94% | +12.92% | -14.23% | +23.86% | -8.51% | +3.65% | +21.77% | -36.40% | -8.82% | +8.61% | +7.16% | -8.56% | +2.84% | +2.12% | -12.15% | +2.13% | -6.86% | +3.18% | -22.48% | +3.18% | -7.03% | +8.25% | +5.55% | +2.29% | -5.46% | +19.28% | +65.95% | +4.21% | n/a |
| Research and Development Revenue | 701K | 636K | 527K | 492K | 490K | 180K | 174K | 232K | 229K | 241K | 213K | 151K | 262K | 243K | 214K | 128K | 176K | 111K | 245K | 257K | 203K | 210K | 262K | 523K | 347K | 418K | 414K | 598.15K | 504.23K | 640.04K | 698.63K | 798.2K | 928.93K | 783.9K | 899.58K | 1.03M | 794.46K | 291.17K | 433.56K |
| Research and Development Revenue Growth | +10.22% | +20.68% | +7.11% | +0.41% | +172.22% | +3.45% | -25.00% | +1.31% | -4.98% | +13.15% | +41.06% | -42.37% | +7.82% | +13.55% | +67.19% | -27.27% | +58.56% | -54.69% | -4.67% | +26.60% | -3.33% | -19.85% | -49.90% | +50.72% | -16.99% | +0.97% | -30.79% | +18.63% | -21.22% | -8.39% | -12.47% | -14.07% | +18.50% | -12.86% | -12.42% | +29.29% | +172.85% | -32.84% | n/a |
| Sales and Marketing Revenue | 11.89M | 13.18M | 12.46M | 11.58M | 11.09M | 8.72M | 7.05M | 5.83M | 5.84M | 5.64M | 5.21M | 5.31M | 5.27M | 5.59M | 4.86M | 5.41M | 5.27M | 3.9M | 6.41M | 6.35M | 6.68M | 6.07M | 6.74M | 7.32M | 7.85M | 8.54M | 8.35M | 9.47M | 8.9M | 11.14M | 11M | 11.94M | 11.24M | 10.42M | 10.51M | 10.61M | 8.43M | 5.04M | 4.71M |
| Sales and Marketing Revenue Growth | -9.78% | +5.77% | +7.56% | +4.50% | +27.18% | +23.56% | +20.95% | -0.10% | +3.58% | +8.20% | -1.98% | +0.89% | -5.78% | +15.14% | -10.18% | +2.56% | +35.30% | -39.26% | +1.04% | -5.01% | +10.05% | -9.94% | -7.86% | -6.75% | -8.17% | +2.35% | -11.87% | +6.40% | -20.05% | +1.27% | -7.90% | +6.20% | +7.90% | -0.88% | -0.89% | +25.83% | +67.41% | +6.83% | n/a |